GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Zacks.com on MSN10h
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...
GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback